EX-10.1



 Exhibit 10.1 

Execution Version 
 Voting
and Support Agreement 
 VOTING AND SUPPORT AGREEMENT, dated as of June 7, 2017 (this “Agreement”), by and between
GL Trade Investment Limited, a company incorporated under the laws of the Cayman Islands (the “Stockholder”), and SciClone Pharmaceuticals, Inc., a Delaware corporation (the “Company”). Capitalized terms used and
not otherwise defined herein shall have the respective meanings ascribed to them in the Merger Agreement (as defined below). 
 Recitals

 WHEREAS, as of the date hereof, the Stockholder is the beneficial owner of 4,750,116 Common Shares (together with such additional
shares of capital stock that become beneficially owned (within the meaning of Rule 13d-3 promulgated under the Exchange Act) by it, whether upon the exercise of options, conversion of convertible securities or otherwise, after the date hereof until
the Expiration Date, the “Subject Shares”); 
 WHEREAS, concurrently with the execution of this Agreement, Silver Biotech
Investment Limited, a company organized under the laws of the Cayman Islands (“Holdco”), Silver Delaware Investment Limited, a Delaware corporation and wholly-owned subsidiary of Holdco (“Merger Sub”), and the
Company are entering into an Agreement and Plan of Merger, dated as of the date hereof (the “Merger Agreement”), pursuant to which, upon the terms and subject to the conditions thereof, Merger Sub will be merged with and into the
Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Holdco; 
 WHEREAS,
concurrently with the execution of this Agreement, the Stockholder is entering into a Rollover Agreement with Holdco and Silver Biotech Holding Limited, a company organized under the laws of the Cayman Islands and the sole shareholder of Holdco
(“Topco”), pursuant to which, the Stockholder has agreed, among other things, to contribute all of the Subject Shares to Holdco immediately prior to the Effective Time in exchange for newly issued shares of Topco (the
“Rollover Agreement”); 
 WHEREAS, the Company Board has unanimously (i) determined that the Merger Agreement and the
transactions contemplated hereby, including the Merger, are advisable and fair to, and in the best interests of, the Company and its stockholders, (ii) adopted the Merger Agreement and the transactions contemplated thereby, including the
Merger, (iii) directed that the Merger Agreement be submitted to the stockholders of the Company for their approval and (iv) resolved to recommend that the stockholders of the Company approve the Merger Agreement; and 

WHEREAS, as a condition and inducement to the willingness of the Company to enter into the Merger Agreement, the Company has required that the
Stockholder enters into this Agreement, and the Stockholder desires to enter into this Agreement to induce the Company to enter into the Merger Agreement; 







 NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements
contained herein, and intending to be legally bound hereby, the parties hereby agree, severally and not jointly, as follows: 
 1. Voting
of Shares. From the period commencing with the execution and delivery of this Agreement and continuing until the Expiration Date, at every meeting of the stockholders of the Company called with respect to any of the following, and at every
adjournment or postponement thereof, and on every action or approval by written consent of the stockholders of the Company with respect to any of the following, the Stockholder shall vote or cause to be voted the Subject Shares that it is entitled
to vote: 
 (a) in favor of the adoption of the Merger Agreement and the approval of the transactions contemplated thereby, including the
Merger; and 
 (b) against any other action or agreement that is not recommended by the Company Board and that would reasonably be expected
to (A) result in a breach of any covenant, representation or warranty or any other obligation or agreement of the Company under the Merger Agreement, (B) result in any of the conditions to the consummation of the Merger under
the Merger Agreement not being fulfilled, or (C) impede, frustrate, interfere with, delay, postpone or adversely affect the Merger and the other transactions contemplated by the Merger Agreement. 

2. Transfer of Shares. The Stockholder covenants and agrees that during the period from the date of this Agreement through the
Expiration Date, it will not, directly or indirectly, (i) transfer, assign, sell, pledge, encumber, hypothecate or otherwise dispose (whether by sale, liquidation, dissolution, dividend or distribution) of or consent to any of the
foregoing (“Transfer”), or cause to be Transferred, any of the Subject Shares, (ii) deposit any of the Subject Shares into a voting trust or enter into a voting agreement or arrangement with respect to the Subject Shares
or grant any proxy or power of attorney with respect thereto that is inconsistent with this Agreement, (iii) enter into any contract, option or other arrangement or undertaking with respect to the Transfer of any Shares or
(iv) take any other action, that would materially restrict, limit or interfere with the performance of the Stockholder’s obligations hereunder. The foregoing restrictions on Transfers of Subject Shares shall not prohibit any such
Transfers by the Stockholder in connection with the transactions contemplated by the Merger Agreement, the Rollover Agreement or the Escrow Agreement. 

3. Additional Covenants of the Stockholder. 

(a) Further Assurances. From time to time and without additional consideration, each party hereto shall (at such party’s sole cost
and expense) execute and deliver, or cause to be executed and delivered, such additional instruments, and shall (at such party’s sole cost and expense) take all reasonable further actions for the purpose of carrying out the intent of this
Agreement. 
 (b) Waiver of Appraisal Rights. The Stockholder hereby waives, to the full extent of the law, and agrees not to assert
any appraisal rights pursuant to Section 262 of the DGCL or otherwise in connection with the Merger with respect to any and all Subject Shares. 







 4. Representations and Warranties of the Stockholder. The Stockholder on its own behalf
hereby represents and warrants to the Company with respect to the Stockholder and its ownership of the Subject Shares as follows: 
 (a)
Authority. The Stockholder has all requisite power and authority to enter into this Agreement and to consummate the transactions contemplated hereby. This Agreement has been duly authorized, executed and delivered by the Stockholder and
constitutes a valid and binding obligation of the Stockholder enforceable in accordance with its terms, except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’
rights generally and by general principles of equity (regardless of whether considered in a proceeding in equity or at law). Other than as provided in the Merger Agreement and any filings by the Stockholder with the Securities and Exchange
Commission, the execution, delivery and performance by the Stockholder of this Agreement does not require any consent, approval, authorization or permit of, action by, filing with or notification to any Governmental Entity, other than any consent,
approval, authorization, permit, action, filing or notification the failure of which to make or obtain would not, individually or in the aggregate, be reasonably expected to prevent or materially delay the consummation of the Merger or the
Stockholder’s ability to observe and perform its material obligations hereunder. 
 (b) No Conflicts. Neither the execution and
delivery of this Agreement, nor the consummation of the transactions contemplated hereby, nor compliance with the terms hereof, will violate, conflict with or result in a breach of, or constitute a default (with or without notice or lapse of time or
both) under any provision of, any trust agreement, loan or credit agreement, note, bond, mortgage, indenture, lease or other agreement, instrument, permit, concession, franchise, license, judgment, order, notice, decree, statute, law, ordinance,
rule or regulation applicable to the Stockholder or to its’s property or assets. 
 (c) The Subject Shares. The Stockholder is
the beneficial owner of, and has good and marketable title to, the Subject Shares free and clear of any and all security interests, liens, changes, encumbrances, equities, claims, options or limitations of whatever nature and free of any other
limitation or restriction (including any restriction on the right to vote, sell or otherwise dispose of such Subject Shares, but excluding any restriction provided by the Rollover Agreement and the Escrow Agreement and any restriction imposed by any
applicable securities laws), other than any of the foregoing that would not prevent or delay the Stockholder’s ability to perform its obligations hereunder. The Stockholder does not own, of record or beneficially, any shares of capital stock of
the Company other than the Subject Shares. Subject to the restrictions under the Rollover Agreement and the Escrow Agreement, the Stockholder have, or will have at the time of the applicable stockholder meeting, the sole right to vote or direct the
vote of, or to dispose of or direct the disposition of, such Subject Shares, and none of the Subject Shares is subject to any agreement, arrangement or restriction with respect to the voting of such Subject Shares that would prevent or delay the
Stockholder’s ability to perform its obligations hereunder (except the obligations under this Agreement). Except for the Rollover Agreement and the Escrow Agreement, (i) there are no agreements or arrangements of any kind, contingent or
otherwise, obligating the Stockholder to Transfer, or cause to be Transferred, any of the Subject Shares and (ii) no Person has any contractual or other right or obligation to purchase or otherwise acquire any of such Subject Shares. 







 (d) Reliance by the Company. The Stockholder understands and acknowledges that the Company
is entering into the Merger Agreement in reliance upon the Stockholder’s execution and delivery of this Agreement. 
 (e)
Litigation. As of the date hereof, to the knowledge of the Stockholder, there is no action, proceeding or investigation pending or threatened against the Stockholder that questions the validity of this Agreement or any action taken or to be
taken by the Stockholder it in connection with this Agreement. 
 5. Representations and Warranties of the Company. The Company
represents and warrants to the Stockholder as follows: 
 (a) Authority. The Company is a corporation duly incorporated, validly
existing and in good standing under the Laws of the State of Delaware and has full corporate power and authority to execute and deliver this Agreement and to consummate the transactions contemplated hereby. The execution and delivery of this
Agreement and the Merger Agreement by the Company and the consummation of the transactions contemplated hereby and thereby have been duly and validly authorized by the Company Board, and no other corporate proceedings on the part of the Company are
necessary to authorize the execution, delivery and performance of this Agreement, the Merger Agreement by the Company and the consummation of the transactions contemplated hereby and thereby. The Company has duly and validly executed this Agreement,
and this Agreement constitutes a legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization or
other similar Laws affecting creditors’ rights generally and by general equitable principles (regardless of whether enforceability is considered in a proceeding in equity or at law). 

6. Termination. This Agreement shall automatically terminate without further action upon the earliest to occur (the “Expiration
Date”) of (A) the Effective Time, (B) the termination of the Merger Agreement in accordance with its terms, (C) the Company Board or any of its committees having made an Adverse Recommendation Change and (D) the written
agreement of the Stockholder and the Company to terminate this Agreement. 
 7. Specific Performance. The Stockholder acknowledges and
agrees that (a) the covenants, obligations and agreements contained in this Agreement relate to special, unique and extraordinary matters, (b) the Company is relying on such covenants in connection with entering into the Merger Agreement
and (c) a violation of any of the terms of such covenants, obligations or agreements will cause the Company irreparable injury for which adequate remedies are not available at law and for which monetary damages are not readily ascertainable.
Therefore, the Stockholder agrees that the Company shall be entitled to an injunction, restraining order or such other equitable relief (without the requirement to post bond) as a court of competent jurisdiction may deem necessary or appropriate to
restrain the Stockholder from committing any violation of such covenants, obligations or agreements. These injunctive remedies are cumulative and shall be the Company’s sole remedy under this Agreement unless the Company shall have sought and
been denied injunctive remedies, and such denial is other than by reason of the absence of violation of such covenants, obligations or agreements. 







 8. Governing Law; Jurisdiction. 

(a) This Agreement shall be deemed to be made in and in all respects shall be interpreted, construed and governed by and in accordance with the
laws of the State of Delaware without regard to the conflicts of law principles thereof. 
 (b) Except as set out below, each of the parties
hereto hereby irrevocably and unconditionally (i) consents to submit to the sole and exclusive jurisdiction of the courts of the State of Delaware or any court of the United States located in the State of Delaware (the “Delaware
Courts”) for any litigation arising out of or relating to this Agreement, or the negotiation, validity or performance of this Agreement, or the transactions contemplated hereby (and agrees not to commence any litigation relating thereto
except in such courts), (ii) waives any objection to the laying of venue of any such litigation in the Delaware Courts and (iii) agrees not to plead or claim in any Delaware Court that such litigation brought therein has been brought in
any inconvenient forum. 
 9. WAIVER OF JURY TRIAL. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS
AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING
OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (i) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH
OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (ii) EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (iii) EACH PARTY MAKES THIS WAIVER VOLUNTARILY AND (iv) EACH
PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 9. 
 10.
Amendment; Waivers. Neither this Agreement nor any term hereof may be amended or otherwise modified other than by an instrument in writing signed by the Company and the Stockholder. No provision of this Agreement may be waived, discharged or
terminated other than by an instrument in writing signed by the party against whom the enforcement of such waiver, discharge or termination is sought. No failure or delay by any party in exercising any right, power or privilege hereunder shall act
as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege hereunder. 

11. Assignment; No Third Party Beneficiaries. This Agreement shall not be assignable or otherwise transferable by a party without the
prior written consent of the other parties, and any attempt to so assign or otherwise transfer this Agreement without such consent shall be void and of no effect. This Agreement shall be binding upon the respective heirs, successors, legal
representatives and permitted assigns of the parties hereto. Nothing in this Agreement shall be construed as giving any Person, other than the parties hereto and their heirs, successors, legal representatives and permitted assigns, any right, remedy
or claim under or in respect of this Agreement or any provision hereof. 







 12. Notices. All notices, claims, demands and other communications hereunder shall be in
writing and shall be deemed given (a) when sent by e-mail of a.pdf attachment (with confirmation of receipt by non-automated reply e-mail from the recipient) (provided that any notice received by e-mail transmission or otherwise at the
addressee’s location on any Business Day after 5:00 p.m. (New York time) shall be deemed to have been received at 9:00 a.m. (New York time) on the next Business Day) or (b) when sent by an internationally recognized overnight
carrier (providing proof of delivery) or when delivered by hand, addressed to the respective parties at the following addresses (or such other address for a party as shall be specified by like notice): 

 

	 	(a)	If to the Company, by email to: 

 SciClone Pharmaceuticals, Inc. 

950 Tower Ln, Foster City, CA 94404 

United States 
 Attention:
Friedhelm Blobel 
 E-mail: FBlobel@SCICLONE.com 

with a copy (which shall not constitute notice) to: 

DLA Piper LLP (US) 
 555 Mission
Street, Suite 2400 
 San Francisco, California 94105-2933 

United States 
 Attention: Howard
Clowes 
 E-mail: howard.clowes@dlapiper.com 

and 
 DLA Piper LLP (US) 

2000 University Avenue 
 East Palo
Alto, California 94303-2214 
 United States 

Attention: Eric Wang 
 E-mail:
eric.wang@dlapiper.com 
  

	 	(b)	if to the Stockholder, by email to: 

 Unit 3001, China World Tower 2 

No. 1 Jian Guo Men Wai Avenue 

Beijing 100004, People’s Republic of China 

Attention: Ms. Shirley Lin 

E-mail: slin@gl-investment.com 







 with a copy (which shall not constitute notice) to: 

Skadden, Arps, Slate, Meagher & Flom LLP 

30/F China World Office 2 

No. 1 Jian Guo Men Wai Ave. 

Beijing, China 100004 
 Attention:
Peter Huang 
 E-mail: Peter.Huang@skadden.com 

13. Severability. Any term or provision of this Agreement which is invalid or unenforceable in any jurisdiction shall, as to that
jurisdiction, be ineffective to the sole extent of such invalidity or unenforceability without rendering invalid or unenforceable the remainder of such term or provision or the remaining terms and provisions of this Agreement in any jurisdiction. If
any provision of this Agreement is so broad as to be unenforceable, such provision shall be interpreted to be only so broad as is enforceable. 

14. Entire Agreement. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and
supersedes all prior agreements and understandings between the parties with respect thereto. No addition to or modification of any provision of this Agreement shall be binding upon either party unless made in writing and signed by both parties. 

15. Section Headings. The article and section headings of this Agreement are for convenience of reference only and are not to be
considered in construing this Agreement. 
 16. Counterparts. This Agreement may be executed in any number of counterparts, each such
counterpart being deemed to be an original instrument, and all such counterparts shall together constitute the same agreement. 

[Remainder of page intentionally left blank] 







 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above
written. 
  

			
	 SCICLONE PHARMACEUTICALS, INC.
  

	By:	 	 /s/ Friedhelm Blobel

		 	Name: Friedhelm Blobel
		 	Title: President and Chief Executive Officer
	  
 GL TRADE INVESTMENT LIMITED

 

	By:	 	 /s/ Hu Chou Hui

		 	Name: Hu Chou Hui
		 	Title: Director


 [Signature Page to Voting and Support Agreement]